| Ticker | EBS |
|---|---|
| ISIN | US29089Q1058 |
| Sector | Atención sanitaria |
| Industria | Drug Manufacturers - Specialty & Generic |
| Mercado | NYSE |
| Capitalización | $412.639.555 |
| Beta | 2,36 |
| Sitio web | https://www.emergentbiosolutions.com |
| CEO | Joseph C. Papa Jr. |
| Fecha de IPO | 15/11/2006 |
| País | US |
| Dirección | 400 Professional Drive, Gaithersburg, MD, 20879 |
| Volumen | 603.317 |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallp...
Emergent Biosolutions, Inc. opera en el sector Healthcare, industria Drug Manufacturers - Specialty & Generic.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones